Prior studies examining cross-sectional tau PET and cognitive decline have focused on specific ROIs, including inferior temporal cortex [12, 13], hippocampus [12], and entorhinal cortex [12, 15] in preclinical AD cohorts, or composite ROIs weighted towards occipital, parietal, and lateral and posterior temporal cortices [11] or temporal and parietal cortices [16] in broader AD cohorts. The gene discussed is MAPT; the disease is Alzheimer disease.